Morgan Stanley Upgrades PTC Therapeutics(PTCT.US) to Buy Rating, Raises Target Price to $67

Futu News09:32 · Ratings

Raymond James, Cantor Bullish on UniQure Following FDA Update

Seeking AlphaDec 11 02:11

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder

BenzingaDec 7 02:10

PTC Therapeutics: Hold Rating Amid Strategic Collaboration With Novartis and Clinical Uncertainties

TipRanksDec 6 13:55 · Ratings

Citi Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Raises Target Price to $32

Futu NewsDec 6 00:35 · Ratings

PTC Therapeutics(PTCT.US) Officer Sells US$5.02 Million in Common Stock

$PTC Therapeutics(PTCT.US)$ Officer Boulding Mark Elliott sold 95,908 shares of common stock on Dec 2, 3, 2024 at an average price of $52.37 for a total value of $5.02 million.Source: Announcement

Futu NewsDec 5 06:23